CTOs on the Move

Flagship Biosciences

www.flagshipbio.com

 
Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data for improved drug development and diagnostics. The company offers a full range of tissue analysis services using its award-winning technology to deliver breakthrough contextual data supported by a team of experienced pathology and scientific experts. It caters to pharmaceutical, biotechnology, and clinical diagnostic companies. Flagship Biosciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Aymii Couzelis
Chief Information Officer Profile

Similar Companies

NexImmune

NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology.

Phosplatin Therapeutics

Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia.

Rain Therapeutics

Rain Therapeutics is a clinical-stage precision oncology company. Our uncompromised dream is to develop and implement the best precision oncology therapies for patients suffering from cancer. We are rooted in this purpose — extending the quality and length of life for cancer patients where we may be their best hope.

Sorrento Therapeutics

Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento recently announced that NantPharma acquired the rights to Cynviloq™, which completed a successful TRIBECA study. Sorrento is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. In December 2014, Sorrento and NantWorks formed a global joint venture, now called Nantibody, to focus on immunotherapies for cancer. Also in December 2014, Sorrento and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast,® a Natural Killer (NK) cell-line based therapy, entered into an agreement to jointly develop CAR.TNK™ (Chimeric Antigen Receptor Tumor-attacking Neukoplast) immunotherapies for the treatment of cancer and infectious diseases. In March 2015, Sorrento entered into a global collaboration with NantCell, a NantWorks company, to discover and develop immunotherapies against tumor neo-epitopes.